Bio-pharmaceutical company ANI Pharmaceuticals Inc (ANI or the Company) (Nasdaq: ANIP) reported on Wednesday that it has received US Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Trimethoprim Tablets USP, 100mg.
ANI said its Trimethoprim Tablets are the generic version of the Reference Listed Drug (RLD) of the same established name.
Nikhil Lalwani, president and chief executive officer of ANI, stated: "As we continue to focus on bringing niche limited-competition products to market, we are pleased to announce the FDA approval and commercialization of Trimethoprim Tablets."
ANI aims to serve patients in need by developing, manufacturing and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition